Analysts Set Smith & Nephew plc (LON:SN) PT at GBX 1,340.11

Smith & Nephew plc (LON:SN) has received an average recommendation of “Hold” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is GBX 1,340.11.

Several analysts recently weighed in on the company. UBS Group reissued a “neutral” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a report on Tuesday, May 5th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,760 target price on shares of Smith & Nephew in a report on Thursday, May 21st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,400 target price on shares of Smith & Nephew in a research report on Thursday. Shore Capital Group reiterated a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,350 price target on shares of Smith & Nephew in a research report on Monday, June 29th.

Smith & Nephew Stock Performance

Shares of SN stock opened at GBX 1,158.50 on Tuesday. The company has a market capitalization of £12.70 billion, a PE ratio of 41.71, a price-to-earnings-growth ratio of 0.46 and a beta of 0.68. The stock’s 50 day moving average is GBX 1,134.48 and its 200-day moving average is GBX 1,195.89. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.